VERONA PHARMA PLC's ticker is VRNA and the CUSIP is 925050106. A total of 71 filers reported holding VERONA PHARMA PLC in Q3 2022. The put-call ratio across all filers is 0.34 and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $916,027 | -15.5% | 56,198 | +9.6% | 0.02% | -8.3% |
| Q2 2023 | $1,084,144 | +59.0% | 51,284 | +51.0% | 0.02% | +71.4% |
| Q1 2023 | $681,937 | -66.6% | 33,961 | -56.6% | 0.01% | -70.2% |
| Q4 2022 | $2,043,079 | +327.4% | 78,189 | +67.1% | 0.05% | +291.7% |
| Q3 2022 | $478,000 | +198.8% | 46,799 | +22.3% | 0.01% | +200.0% |
| Q2 2022 | $160,000 | – | 38,280 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 4,249,918 | $69,273,663 | 7.59% |
| Aisling Capital Management LP | 1,115,352 | $18,180,238 | 7.49% |
| NEA Management Company, LLC | 5,108,563 | $91,031,474 | 7.03% |
| Octagon Capital Advisors LP | 2,369,000 | $38,614,700 | 5.93% |
| Knoll Capital Management, LLC | 200,000 | $3,260,000 | 3.38% |
| Frazier Life Sciences Management, L.P. | 3,014,349 | $49,133,889 | 3.26% |
| Perceptive Advisors | 4,007,197 | $65,317,311 | 2.18% |
| RA Capital Management | 6,317,990 | $102,983,237 | 2.03% |
| Deep Track Capital, LP | 3,187,415 | $51,954,865 | 2.00% |
| Carlyle Group Inc. | 2,457,500 | $40,008,100 | 1.74% |